Opus Genetics, Inc.

# Signal Note: Perceptive Advisors Initiates 4.3M Share Position in Opus Genetics Perceptive's $8.7M entry into Opus signals conviction in the biotech's inherited retinal disease (IRD) pipeline, likely driven by upcoming clinical data or regulatory milestones. Edelman's fund has demonstrated strong selectivity in clinical-stage bets, suggesting meaningful near-term catalysts justify the ~4% stake entry point.